PP
LPCN icon

PDT Partners’s Lipocine LPCN Stock Holding History

PDT Partners’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,800
Closed -$186K – 545
2017
Q1 		$186K Buy
+2,800
New +$182K 0.01% 445

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PDT Partners's LPCN Position: Q2 2017 in Review

PDT Partners sold out of Lipocine (LPCN) in Q2 2017, closing a stake of 2,800 shares — an estimated $186K sold.

PDT Partners first reported a position in LPCN in Q1 2017 and held it in 1 quarter. The position peaked at $186K in Q1 2017. 42 funds tracked by Wall St. Rank hold LPCN as of Q2 2017.

  • PDT Partners reported no remaining Lipocine position as of Q2 2017 after selling out during the quarter.
  • PDT Partners sold 2,800 Lipocine shares in Q2 2017, an estimated $186K.
  • PDT Partners first reported a position in Lipocine in Q1 2017 and held it in 1 quarter.
  • PDT Partners's Lipocine position peaked at $186K in Q1 2017.
  • 42 funds tracked by Wall St. Rank held Lipocine as of Q2 2017.

Based on PDT Partners's 13F filing for Q2 2017, filed 14 Aug 2017.